W ilms' tumor gene 1 (WT1) is a transcription factor first found in Wilms' tumor of the kidney, where it acts as a tumor suppressor gene. 1, 2 The gene is located in chromosome 11p13 and encodes a zinc-finger transcription factor. WT1 acts as a critical regulator of organogenesis in the urogenital, cardiac, and nervous systems. 3 WT1 also plays a role in regulation of hematopoietic development. 4 Recently, overexpression of WT1 was found in solid and hematologic malignancies, [5] [6] [7] [8] such as acute leukemia 9, 10 (acute myeloid leukemia and acute lymphoblastic leukemia) and in myelodysplastic syndrome. In childhood acute leukemia, overexpression of WT1 was correlated with worse prognosis. 11 Currently, WT1 serves as a marker of prognosis and was found to be a reliable marker to follow up minimal residual disease in acute leukemia. 12, 13 WT1 was found recently to be involved in angiogenesis. During hypoxia, WT1 is activated by hypoxia-inducible factor 1. 14 WT1 can activate nestin 15 and ETS-1, 16 known angiogenic factors. WT1 was also shown to regulate the VEGF gene promoter. 17 In-vitro experiments showed that WT1 plays a role in regulation of endothelial cell proliferation and migration. 16 Endothelial WT1 expression was detected in 95% of 113 tumors of various origins, 16 but there are no data concerning the involvement of WT1 in angiogenesis in lymphoproliferative tumors.
During the last years, major developments have been achieved in understanding the biology of Hodgkin lymphoma (HL). [18] [19] The microenvironment of this disease is now recognized to play a central role in its pathogenesis, as the malignant Hodgkin Reed-Sternberg cells are only a minority in the affected tissue, outnumbered by non-neoplastic background composed of mixed inflammatory, endothelial cells and fibrotic component. [18] [19] It is indeed the Hodgkin Reed-Sternberg cells that elaborate cytokines that act as paracrine or autocrine factors that assist cell survival, proliferation, and angiogenesis.
A correlation between angiogenesis and poor prognosis in HL was reported. 20, 21 The aim of this study was to explore the involvement of WT1 in HL.
DESIGN AND METHODS

Reagents
Anti-human VEGF and neuropilin-1 (NP1) antibodies were purchased from Imgenex (San Diego, CA), anti human WT1-Novocast (Littleton, CO). The Histostain+ immunohistochemistry kit was purchased from Invitrogen (Camarillo, CA).
Patients
Lymph node biopsies from 20 Hodgkin patients and 10 reactive lymph nodes were enrolled in this study. The biopsies were diagnosed and stored in the archive of the Pathology Department of the Bnai-Zion Medical Center, Haifa, Israel. Hodgkin disease was diagnosed and subtyped according to the World Health Organization classification system. The reactive lymph nodes were obtained from surgical margins of colectomies due to colon cancer, without tumoral involvement.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were sliced 5 mm by microtome. The slides were deparaffinized by xylene and then rehydrated by absolute ethanol, 96% ethanol, 70% ethanol, and 2 quick distilled water washes. The antigen retrieval was done by cooker pressure in EDTA solution, 2 mM, pH-8.0 or citric acid, pH-6.0. H 2 O 2 3% in methanol was used to block endogenous hydrogen peroxidase. Primary antibodies were incubated with the slides as follows: anti-human NP1 (1:10), anti-human WT1 (1:50), and anti-human VEGF-A (1:30). Secondary antibody and staining was done using the commercial kit of Histostain+, according the manufacturer instructions. Slides that were used as specificity controls underwent the same procedure without primary antibodies. No staining was observed in these controls (data not shown).
The extent of angiogenesis was evaluated by mean blood vessels density per power field [mean vascular density (MVD)], using the CD34 antibody as the gold standard marker.
The intensity score of staining of WT1/NP1/VEGF was determined by expert pathologists. The score scale represents the intensity of staining ("qualitative score": 1 to 3 scale) and the percent of vessels stained ("quantitative score": scale of 1 to 3-score "1" represents 0% to 33% stained vessels; "2" represents 34% to 66%; and "3" represents 67% to 100%). The WT1 expression scale is the multiplication of these 2 scores (qualitative and quantitative scores), and ranges between 1 and 9. A score of "0" represents negative staining.
Statistical analysis was done using the R statistical software (http://www.r-project.org) for correlation and Wilcoxon tests.
The nonparametric Wilcoxon test (also known as the Mann-Whitney U test) was used, because the sample size was small and the data could not be assumed to be normally distributed. Two-tailed P-values of 0.05 or less were considered to be statistically significant.
RESULTS
Biopsies from 20 Hodgkin patients were examined in this study. Table 1 summarizes the patients' histologic and staging characterization. As can be shown in this table: 10 patients were males and 10 females, and the histologic subtypes were nodular sclerosis in 9 patients (45%), lymphocytic rich in 2 patients (10%), lymphocytic depleted in 2 patients (10%), and mixed cellularity in 6 patients (30%).
In 95% (19/20) of the malignant biopsies, WT1 was expressed in endothelial cells. However, WT1 was not expressed in the Reed-Sternberg cells (Fig. 1, black  arrows) .
The average of WT1 expression scale was higher in the malignant lymph nodes than in reactive lymph nodes (2.2 vs. 1.85; P = 0.21-Wilcoxon test, positive statistical trend). Among the reactive lymph nodes, only 1 scored 6 in the staining score, whereas all the rest nodes scored 0 to 2. In contrast, the Hodgkin nodes scored 1 to 9. Table 2 summarizes the scoring of MVD and WT1 staining in the Hodgkin nodes and the reactive nodes.
We found a positive correlation between WT1 expression scale and the angiogenesis scale (r = 0.53) that was statistically significant (P = 0.014). As the number of blood vessels increases, the expression of WT1 is more intense. NP1 was expressed in 92% (13/14) of the malignant lymph nodes and in none of the reactive lymph nodes. NP1-positive endothelial cells were also WT1 positive.
VEGF was expressed in 71% (10/14) of the malignant lymph nodes. In the reactive lymph nodes, VEGF was stained in higher intensity compared with the malignant lymph nodes. The MVD was higher in the reactive lymph nodes (Fig. 2) .
DISCUSSION
WT1 was originally considered as a tumor suppressor gene in renal malignancies. But more recently, a potential oncogenic role of WT1 was described in a variety of solid tumors. WT1 is transcriptionally regulated by hypoxia-inducible factor 1 in vascular endothelial cells under conditions of hypoxia. 12, 14 It is required for blood vessel formation during embryonic development, and it is expressed in microvessel formation. 22 Thus, it was suggested that WT1 may be involved actively in proliferation of endothelial cells and vessel formation rather than being only a novel endothelial cell marker. The expression of WT1 in endothelia of several solid malignancies further strengthens the hypothesis of its involvement in angiogenesis. 16 Here, we found, for the first time to our knowledge, that WT1 is expressed in the endothelia of HL. The expression of WT1 was positively correlated with the extent of angiogenesis in the malignant lymph nodes and was more intense in the Hodgkin lymph nodes than in the reactive nodes. To explore the relation of WT1 to other angiogeneic factors, we tested the expression of NP1 and VEGF in the Hodgkin lymph nodes.
VEGF was expressed in both the Hodgkin and the reactive lymph nodes. The staining was more intense in the reactive nodes. The high level of VEGF and MVD in the reactive nodes may be due to inflammatory process in the reactive node. NP1 is a known functional VEGF receptor and augments its angiogenic effects. In our study, we found that NP1 was expressed in the Hodgkin lymph nodes but not in the reactive lymph nodes. Our hypothesis was therefore that NP1 and WT1, perhaps as a compensatory mechanism for the low VEGF expression, may augment the angiogenic biological effect of VEGF, so that a lower amount of VEGF may produce more pronounced angiogenic activity in the presence of NP1 and WT1.
In summary, in this study, we found that WT1 is expressed in endothelial cells of neovascularization in HL. This finding is in line with recent data concerning the role of WT1 in angiogenesis in solid tumors. On the basis of our preliminary findings, we suggest that WT1 could be a proangiogenic factor that may participate in angiogenic process of HL.
Future studies, with a larger sample size, are needed to investigate further the clinical correlations and potential clinical uses of WT1 in HL.
